This is a Phase I, single-center, randomized, double-blind, placebo-controlled SAD/MAD study to evaluate safety, tolerability, and PK of Intravenously Administered PTT-121 in healthy Chinese adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
84
PTT-121 will be administered intravenously
Matching placebo identical to PTT-121 formulation but without the active pharmaceutical ingredient
Peking University Third Hospital
Beijing, Beijing Municipality, China
Number of Participants With Treatment-emergent Adverse Events
Time frame: SAD: up to 15 days MAD: up to 21 days
Pharmacokinetics of PTT-121
The drug concentrations of PTT-121will be determined at multiple time points after drug administration.
Time frame: SAD: up to 2 days MAD: up to 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.